John Moroney, MD, specializes in the diagnosis and treatment of gynecologic cancers, with a focus on providing skilled and personalized longitudinal care. He believes that access to innovative surgical techniques and targeted medical therapies are essential in achieving optimal outcomes.
Dr. Moroney is the principal investigator (PI) at the University of Chicago for NRG Oncology, a National Cancer Institute-supported clinical trials cooperative group. He also serves as the PI for numerous other industry-sponsored clinical trials.
Loyola University Stritch School of Medicine
MDWalter Reed National Military Medical Center
InternshipWalter Reed National Military Medical Center
ResidencyMD Anderson Cancer Center
FellowshipNCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024.
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 10; 22(8):512-519.
PMID: 39413835NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8):1234-1245.
PMID: 38127487Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer.
Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23):2162-2174.
PMID: 38055253A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 176:16-24.
PMID: 37418832Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322.
PMID: 35900726Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022 07 15; 132(14).
PMID: 35671108A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
PMID: 35063278Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
PMID: 34168049Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
PMID: 33028595Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
View All Publications
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21):5631-5637.
PMID: 32723836